Literature DB >> 15173968

[Serpiginous choroiditis: clinical course and treatment].

B Marcuello Melendo1, C Torrón Fernández-Blanco, S Pérez Oliván, O Ruiz Moreno, E Ferrer Novella, F M Honrubia López.   

Abstract

PURPOSE: To evaluate the clinical evolution and treatment of serpiginous choroiditis in 11 diagnosed patients.
METHODS: Retrospective study of 11 cases diagnosed with serpiginous choroiditis in our area, from 1980 to the present. We analyzed age at onset of symptoms, systemic diseases, ophthalmological symptoms at presentation, the location of lesions, initial and final visual acuity, recurrences, treatment régime and development of subretinal neovascularization. A complete ophthalmological examination and fluorescein angiograms were performed in all of them.
RESULTS: The mean period of follow-up was 4 years. Average age was 56 years, predominantly in men (10/1). Five patients had known ischemic cardiopathy and systemic hypertension, one patient underwent a kidney transplant. All of them were treated with oral prednisone (1-1.5 mg/kg/daily) in the active stages. Three patients received triple therapy (prednisone, cyclosporine and azathioprine) that did not prevent the recurrences. Five patients developed a subretinal neovascularization, bilateral in three of them.
CONCLUSIONS: The serpiginous choroiditis is a rare entity and the visual outcome prognosis is determined by the macular involvement. Men are predominantly affected in our series and corticosteroid treatment is effective in acute inflammatory episodes. Recurrences could not be prevented by triple therapy with immunosuppressive agents in our three patients.

Entities:  

Mesh:

Year:  2004        PMID: 15173968     DOI: 10.4321/s0365-66912004000500008

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  1 in total

1.  Fungal infection in patients with serpiginous choroiditis or acute zonal occult outer retinopathy.

Authors:  Diana Pisa; Marta Ramos; Patricia García; Remberto Escoto; Rafael Barraquer; Susana Molina; Luis Carrasco
Journal:  J Clin Microbiol       Date:  2007-11-14       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.